Vascular malformations syndromes: an update.
暂无分享,去创建一个
T. Montero-Vílchez | S. Arias-Santiago | A. Molina-Leyva | A. Martínez-López | J. Tercedor-Sánchez | L. Salvador-Rodríguez | A. Molina‐Leyva
[1] Yizhong Wang,et al. Magnetically Controlled Capsule Endoscopy in Children: A Single-center, Retrospective Cohort Study. , 2019, Journal of pediatric gastroenterology and nutrition.
[2] E. Barbi,et al. Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature , 2019, Pediatric Drugs.
[3] S. Blaise,et al. Photoacoustic imaging as an innovative technique for the exploration of blue rubber bleb naevus , 2019, The British journal of dermatology.
[4] Jun Yang,et al. Endoglin is a conserved regulator of vasculogenesis in zebrafish – implications for hereditary haemorrhagic telangiectasia , 2019, Bioscience reports.
[5] J. Teng,et al. Successful treatment of spindle cell hemangiomas in a patient with Maffucci syndrome and review of literatures , 2019, Dermatologic therapy.
[6] B. Khaitan,et al. Unsatisfactory response to sirolimus in Maffucci syndrome‐associated spindle cell hemangiomas , 2019, Dermatologic therapy.
[7] A. Nordgren,et al. Early activating somatic PIK3CA mutations promote ectopic muscle development and upper limb overgrowth , 2019, Clinical genetics.
[8] O. Gerke,et al. Long-Term Single-Center Retrospective Follow-Up After Embolization of Pulmonary Arteriovenous Malformations Treated Over a 20-year Period: Frequency of Re-canalization with Various Embolization Materials and Clinical Outcome , 2019, CardioVascular and Interventional Radiology.
[9] C. Shovlin,et al. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia , 2019, Orphanet Journal of Rare Diseases.
[10] P. Ewings,et al. Novel use of tranexamic acid to reduce the need for Nasal Packing in Epistaxis (NoPac) randomised controlled trial: research protocol , 2019, BMJ Open.
[11] T. Matsumoto,et al. Gastrointestinal: Endoscopic injection sclerotherapy for duodenal vascular malformation in blue rubber bleb nevus syndrome , 2019, Journal of gastroenterology and hepatology.
[12] J. Kjeldsen,et al. Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series. , 2019, Rhinology.
[13] P. Lapunzina,et al. Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly , 2018, The Journal of experimental medicine.
[14] Brian A Palmer,et al. Pain, psychiatric comorbidities, and psychosocial stressors associated with Klippel‐Trenaunay syndrome , 2018, Journal of the American Academy of Dermatology.
[15] Maneesh C. Patel,et al. Uptake and radiological findings of screening cerebral magnetic resonance scans in patients with hereditary haemorrhagic telangiectasia. , 2018, Intractable & rare diseases research.
[16] Julie C. Sapp,et al. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum , 2018, Genetics in Medicine.
[17] Osamah Alwalid,et al. Radiological Aspect of Klippel-Trénaunay Syndrome: A Case Series With Review of Literature , 2018, Current Medical Science.
[18] Ralitsa R. Madsen,et al. Cancer-Associated PIK3CA Mutations in Overgrowth Disorders , 2018, Trends in molecular medicine.
[19] P. Jervis,et al. The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. , 2018, The Journal of laryngology and otology.
[20] G. Chaudry,et al. Pulmonary thromboembolic events in patients with congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and spinal/skeletal abnormalities and Klippel-Trénaunay syndrome. , 2018, Journal of vascular surgery. Venous and lymphatic disorders.
[21] Laureline Berteloot,et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome , 2018, Nature.
[22] P. Sutphin,et al. Pulmonary arteriovenous malformations: diagnosis. , 2018, Cardiovascular diagnosis and therapy.
[23] J. Rimmer,et al. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review. , 2018, Rhinology.
[24] A. Mansilha,et al. Vascular malformations: classification, diagnosis and treatment. , 2018, International angiology : a journal of the International Union of Angiology.
[25] J. Clayton-Smith,et al. Hypoglycaemia represents a clinically significant manifestation of PIK3CA‐ and CCND2‐associated segmental overgrowth , 2018, Clinical genetics.
[26] D. Zurakowski,et al. Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA‐related overgrowth spectrum , 2018, Clinical genetics.
[27] J. Mulliken,et al. A cross‐sectional survey of long‐term outcomes for patients with diffuse capillary malformation with overgrowth , 2017, Journal of the American Academy of Dermatology.
[28] L. Biesecker,et al. Pathogenetic insights from quantification of the cerebriform connective tissue nevus in Proteus syndrome , 2017, Journal of the American Academy of Dermatology.
[29] C. Shields,et al. CHOROIDAL MELANOMA IN PHAKOMATOSIS PIGMENTOVASCULARIS WITH KLIPPEL–TRENAUNAY SYNDROME , 2017, Retina.
[30] M. Mackay,et al. Screening for Sturge‐Weber syndrome: A state‐of‐the‐art review , 2018, Pediatric dermatology.
[31] S. Middeldorp,et al. Complications of pregnancy and labour in women with Klippel–Trénaunay syndrome: a nationwide cross‐sectional study , 2017, BJOG : an international journal of obstetrics and gynaecology.
[32] A. D. Rodríguez,et al. Análisis del síndrome de Sturge-Weber: estudio retrospectivo de múltiples variables asociadas , 2017 .
[33] Marilyn M. Li,et al. Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next-Generation Sequencing Panel. , 2017, The Journal of molecular diagnostics : JMD.
[34] Z. Rancic,et al. Parkes Weber syndrome—Diagnostic and management paradigms: A systematic review , 2017, Phlebology.
[35] M. Dalsing,et al. Diagnosis and management of the venous malformations of Klippel-Trénaunay syndrome. , 2017, Journal of vascular surgery. Venous and lymphatic disorders.
[36] Julie C. Sapp,et al. Characterization of thrombosis in patients with Proteus syndrome , 2017, American journal of medical genetics. Part A.
[37] J. Mulliken,et al. Sonographic screening for Wilms tumor in children with CLOVES syndrome , 2017, Pediatric blood & cancer.
[38] Julie C. Sapp,et al. Quantifying survival in Patients with Proteus Syndrome , 2017, Genetics in Medicine.
[39] C. Kin,et al. Say What? Bannayan–Riley–Ruvalcaba Syndrome Presenting with Gastrointestinal Bleeding Due to Hamartoma-Induced Intussusception , 2017, Digestive Diseases and Sciences.
[40] M. H. Ali,et al. Pathophysiology, diagnosis, and management of glaucoma associated with Sturge–Weber syndrome , 2017, International Ophthalmology.
[41] C. Eng,et al. Breast cancer risk and clinical implications for germline PTEN mutation carriers , 2017, Breast Cancer Research and Treatment.
[42] R. Weksberg,et al. Molecular Mechanisms of Childhood Overgrowth , 2013, American journal of medical genetics. Part C, Seminars in medical genetics.
[43] J. Glowacki,et al. Hemangiomas and Vascular Malformations in Infants and Children: A Classification Based on Endothelial Characteristics , 1982, Plastic and reconstructive surgery.